YEAP SIEW KUEN
No ORCID on file
· 32 papers in corpus
· active 2008-2009
Frequent coauthors
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2009
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined he rein, and especially to EP2 antagonist compounds, to their use in medicine, particularly i…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined he rein, and especially to EP2 antagonist compounds, to their use in medicine, particularly i…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined he rein, and especially to EP2 antagonist compounds, to their use in medicine, particularly i…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined he rein, and especially to EP2 antagonist compounds, to their use in medicine, particularly i…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined he rein, and especially to EP2 antagonist compounds, to their use in medicine, particularly i…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined he rein, and especially to EP2 antagonist compounds, to their use in medicine, particularly i…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined he rein, and especially to EP2 antagonist compounds, to their use in medicine, particularly i…
2008
The present invention relates to a class of EP2 antagonist azetidines of general formula (I) wherein the variables and substituents are as defined he rein, and especially to EP2 antagonist compounds, to their use in medicine, particularly i…
2008
The invention relates to EP2 antagonist azetidines of formula (I) wherein Ar, R, X, and Z are as defined herein, to their use in medicine, particularly in the treatment of endometriosis and/or uterine fibroids, to intermediates useful in th…